Boston Scientific Corporation $BSX Shares Sold by Frank Rimerman Advisors LLC

Frank Rimerman Advisors LLC lowered its position in Boston Scientific Corporation (NYSE:BSX) by 4.7% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 20,103 shares of the medical equipment provider’s stock after selling 989 shares during the quarter. Frank Rimerman Advisors LLC’s holdings in Boston Scientific were worth $2,159,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of BSX. GAMMA Investing LLC raised its holdings in Boston Scientific by 15.4% in the second quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock valued at $3,167,000 after acquiring an additional 3,932 shares in the last quarter. MRA Advisory Group acquired a new stake in shares of Boston Scientific in the 2nd quarter valued at $273,000. Bank of New Hampshire lifted its position in shares of Boston Scientific by 552.0% during the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock worth $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd grew its stake in shares of Boston Scientific by 1.6% during the first quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock worth $37,143,000 after purchasing an additional 5,704 shares in the last quarter. Finally, New England Research & Management Inc. purchased a new position in Boston Scientific in the second quarter valued at $1,133,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX opened at $101.71 on Tuesday. The company’s 50 day simple moving average is $99.59 and its 200-day simple moving average is $102.55. The firm has a market cap of $150.78 billion, a PE ratio of 54.39, a price-to-earnings-growth ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The firm had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. Boston Scientific’s revenue for the quarter was up 20.3% on a year-over-year basis. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Insider Activity

In related news, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction dated Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the transaction, the executive vice president owned 178,342 shares in the company, valued at $17,739,678.74. This trade represents a 21.90% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 175,782 shares of company stock valued at $17,742,314 in the last quarter. Insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

A number of analysts have issued reports on BSX shares. Robert W. Baird lifted their price target on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a report on Wednesday, October 1st. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 11th. Erste Group Bank cut shares of Boston Scientific from a “buy” rating to a “hold” rating in a report on Friday, October 3rd. Wells Fargo & Company boosted their price objective on shares of Boston Scientific from $124.00 to $125.00 and gave the stock an “overweight” rating in a research report on Thursday, October 23rd. Finally, Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $123.77.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.